| OALBC0605 | An HIV Prevention model focused on key populations alone will not end HIV/AIDS in Thailand by 2030 | Oral abstract session with live Q&A | Population-specific interventions for HIV prevention |
| OALBC0604 | High in-hospital mortality in SARS-CoV-2 infected patients living with HIV during pre-Delta, Delta and Omicron variant waves: finding from the WHO Global Clinical Platform for COVID-19 | Oral abstract session with live Q&A | Epidemiology of COVID-19 |
| OALBC0603 | Acceptability of CAB-LA in cisgender female adolescents in South Africa, Uganda, and Zimbabwe (HPTN 084-01) | Oral abstract session with live Q&A | Population-specific interventions for HIV prevention |
| OALBC0602 | Should social network testing be offered as an additional HIV testing approach? A GRADE systematic review and meta-analysis | Oral abstract session with live Q&A | HIV testing |
| OALBB0505 | Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OALBB0504 | Risks of hypertension with first-line dolutegravir (DTG) and tenofovir alafenamide (TAF) in the NAMSAL and ADVANCE trials | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OALBB0503 | Increasing second-line antiretroviral therapy options for children with HIV in Africa: week-96 efficacy and safety results of the CHAPAS-4 randomised trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OALBB0502 | A prospective, randomized trial to assess a protease inhibitor–based regimen switch strategy to manage integrase inhibitor–related weight gain | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OALBA0505 | Anti-SIV Env RhmAbs +/- CD8a depletion and N-803 in ART-suppressed rhesus macaques leads to post-treatment control of viremia in a subset of animals | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OALBA0504 | Absence of viral rebound for 18 months without antiretrovirals after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells to treat a biphenotypic sarcoma | Oral abstract session with live Q&A | Novel treatment and prevention strategies |